Investigative Medicine Division
We aim to rapidly translate innovative science into patient benefit across a range of disease areas. From molecular biology and target discovery, through to interventional medicine and informing policy, we bring together researchers in a diverse range of specialties including acute stroke, dementia and immunology.
Molecular Basis for the Recognition of HIV Nef138-8 Epitope by a Pair of Human Public T Cell Receptors.
Ma K. et al, (2022), J Immunol
Major haemorrhage: past, present and future.
Shah A. et al, (2022), Anaesthesia
IFITM3 restricts virus-induced inflammatory cytokine production by limiting Nogo-B mediated TLR responses.
Clement M. et al, (2022), Nat Commun, 13
Lymphatic endothelia stakeout cryptic stem cells.
Antanaviciute A. et al, (2022), Cell Stem Cell, 29, 1292 - 1293
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
Hadjihambi A. et al, (2022), J Hepatol
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease
1 December 2021
Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.
5 August 2022
Co-founded by Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.
22 July 2022
The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.
16 June 2022
Four related projects aim to unravel how the iron we eat shapes how the immune system develops and responds to vaccines.